Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C/D (Excluding In-transit) Melanoma

NCT02858921 is registered in ClinicalTrials.gov with Melanoma Institute Australia as lead sponsor.

NCT NCT02858921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02858921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C/D (Excluding In-transit) Melanoma
Lead sponsor
Melanoma Institute Australia
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 8, 2017
Completion date
November 30, 2027
Enrollment
60 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma